Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Winkelmann

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
CNS Neuroscience & Therapeutics|January 10, 2018
Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulatorInes C Angerer, Michael Hecker, Dirk Koczan, et al.
Journal of Neuroimmunology|December 4, 2014
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysisSteffi Grey Née Cotte, Anke Salmen Née Stroet, Nico von Ahsen, et al.
Frontiers in Immunology|February 14, 2025
Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicatorsMichael Hecker, Brit Fitzner, Isis Ludwig-Portugall, et al.
Neurogenetics|November 19, 2011
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sampleChristina M Lill, Brit-Maren M Schjeide, Denis A Akkad, et al.
Journal of Neurology|October 13, 2016
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndromeAndré M Huss, Steffen Halbgebauer, Patrick Öckl, et al.
Journal of Neuroinflammation|November 3, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcomeSven Jarius, Ingo Kleiter, Klemens Ruprecht, et al.
Journal of Neuroinflammation|October 30, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and originSven Jarius, Klemens Ruprecht, Ingo Kleiter, et al.
Journal of Neuroinflammation|October 30, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeSven Jarius, Klemens Ruprecht, Ingo Kleiter, et al.
Neurogenetics|March 19, 2014
Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosisChristina M Lill, Marcel Schilling, Sara Ansaloni, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 4, 2024
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacksCarolin Schwake, Theodoros Ladopoulos, Vivien Häußler, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
CNS Neuroscience & Therapeutics|January 10, 2018
Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulatorInes C Angerer, Michael Hecker, Dirk Koczan, et al.
Journal of Neuroimmunology|December 4, 2014
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysisSteffi Grey Née Cotte, Anke Salmen Née Stroet, Nico von Ahsen, et al.
Frontiers in Immunology|February 14, 2025
Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicatorsMichael Hecker, Brit Fitzner, Isis Ludwig-Portugall, et al.
Neurogenetics|November 19, 2011
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sampleChristina M Lill, Brit-Maren M Schjeide, Denis A Akkad, et al.
Journal of Neurology|October 13, 2016
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndromeAndré M Huss, Steffen Halbgebauer, Patrick Öckl, et al.
Journal of Neuroinflammation|November 3, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcomeSven Jarius, Ingo Kleiter, Klemens Ruprecht, et al.
Journal of Neuroinflammation|October 30, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and originSven Jarius, Klemens Ruprecht, Ingo Kleiter, et al.
Journal of Neuroinflammation|October 30, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeSven Jarius, Klemens Ruprecht, Ingo Kleiter, et al.
Neurogenetics|March 19, 2014
Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosisChristina M Lill, Marcel Schilling, Sara Ansaloni, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 4, 2024
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacksCarolin Schwake, Theodoros Ladopoulos, Vivien Häußler, et al.
Pageof 5